What is Alnylam Pharmaceuticals's business segments — SG&A?

Alnylam Pharmaceuticals (ALNY) reported business segments — SG&A of $347.92M in Q2 2026.

What does business segments — SG&A mean?

This metric reflects the total operating expenses associated with selling, general, and administrative functions, including marketing, commercialization efforts, and corporate overhead. It provides insight into the costs required to support the company's commercial operations and infrastructure. Tracking this expenditure helps investors evaluate the company's operational leverage and the efficiency of its commercial scaling efforts.

Alnylam Pharmaceuticals ALNY Business Segments — SG&A

Similar metrics at other companies

VCELSingle Reportable Segment — SG&A

$48.48M+15.7%

AGIOReportable Segment — SG&A

$51.55M+12.4%

TVTXReportable Segment — SG&A

$80.25M+32.8%

INDVReportable Segment — SG&A

$124M-6.8%

ZVRAReportable Segment — SG&A

$14.35M+19.8%

MDXGReportable Segment — SG&A

$59.78M-6.8%

Other financials

Income statement

See full

Revenue$1.3B+66.9%

Gross profit$992.7M+57.2%

Operating income$231.4M+1,529%

Net income$164.5M+348%

EPS (diluted)$1.21+337%

Balance sheet

See full

Cash & equivalents$1.7B+53.2%

Total debt$256.4M-5.2%

Total equity$1.4B+440%

Total assets$5.6B+21.7%

Cash flow

See full

Operating cash flow$326.7M+113%

CapEx$34.7M+143%

Free cash flow$292.0M+109%

Valuation

See full

Market cap$38.51B-10.7%

Enterprise value$37.05B-12.3%

P/E52.5×—

P/S8×-9.5×

Profitability

See full

Gross margin79.8%-4.1pp

Operating margin20.8%+16.5pp

Net margin15.3%+10.7pp

FCF margin16.5%+14.8pp

Returns & leverage

See full

Return on equity91.4%—

Debt / equity0.2×-0.9×

Current ratio3.1×+0.3×

Where this comes from

Reported directly by Alnylam Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The official record: Alnylam Pharmaceuticals’s 10-Q, filed July 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alnylam Pharmaceuticals's business segments — sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Alnylam Pharmaceuticals's business segments — SG&A?: Alnylam Pharmaceuticals (ALNY) reported business segments — SG&A of $347.92M in Q2 2026.
What does business segments — SG&A mean?: This metric reflects the total operating expenses associated with selling, general, and administrative functions, including marketing, commercialization efforts, and corporate overhead. It provides insight into the costs required to support the company's commercial operations and infrastructure. Tracking this expenditure helps investors evaluate the company's operational leverage and the efficiency of its commercial scaling efforts.